Drs. Wyatt, Chi and their teams have a new Cancer Discovery publication, "Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer," in which they identify novel genomic biomarkers that could ultimately help decide whether patients with advanced prostate cancer should receive abiraterone or enzalutamide.
Vancouver Prostate Centre investigators were highly successful, receiving 6 Canadian Institutes of Health Research (CIHR) research grants in the Fall 2017 Project Grant competition for a total of $3.48 million over five years.
The funded projects are:
Read the original VCHRI News story here.
Dr. Martin Gleave was recently named a member of the Order of Canada, one of the country’s highest civilian honours, for his leadership role in developing new treatments for prostate cancer and for his research on the mechanisms involved in the development of treatment resistance in cancer.
Dr. Alex Wyatt has been awarded a 2017 CIHR Early Career Investigator Award. His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies. The funding partners are the Institute of Cancer Research and AstraZeneca Canada Inc., and the award is for $345,000 over 3 years.
A drug development collaboration utilizing cryo-electron microscopy, lead by Dr. Artem Cherkasov and including the Vancouver Prostate Centre, the BC Cancer Agency, the ASTRID structural biology consortium within the Life Sciences Institute at UBC, and the Centre for Drug Research and Development, is the subject of a Nov. 18th a VCHRI News story.
Federal Minister of Justice and Attorney General of Canada Jody Wilson-Raybould today announced UBC's successful CFI Infrastructure Fund awardees. The largest grant, $9 million, was awarded to a research program led by Dr. Artem Cherkasov, titled Accelerated Drug Discovery Using Clinical Translation (ADDUCT).
In the last week, two VPC researchers have been awarded grants to fund research projects aimed at improving the treatment prostate cancer.
Thee publications out of the VPC describing work towards the development of new therapeutics were published in the last week.
The results of research awards from two agencies today demonstrate the VPC's successful translation of basic research into discoveries that are moving to clinical applications.